8-K filed Aug 7, 2026 at 07:00 ET
ANI Pharmaceuticals reported record Q2 2026 revenue of $266.0M (+25.9% YoY), beating consensus of $260.1M. Adjusted non-GAAP diluted EPS of $2.21 beat the $2.04 estimate by 8.2%. Cortrophin Gel revenue surged 43.5% to $117.1M, driven by strong demand across existing specialties and early positive signals from the gout expansion. The company reaffirmed full-year total revenue guidance of $1,080-$1,140M and adjusted EBITDA of $285-$300M, but narrowed Cortrophin Gel guidance to $520-$540M (from $540-$575M), reflecting a modest trim to the top end. Overall, a strong beat with solid execution, though the Cortrophin guidance adjustment may temper enthusiasm.